Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional support of US$1.6M from The Danish Growth Fund (Vækstfonden) and the Danish Innovation Fund (Innovationsfonden), allowing Lop hora to complete pre-clinical development of its first-in-class lead candidate LPH-5, which is expected to enter Phase I studies in early 2022.